



MANAGEMENT DISCUSSION AND ANALYSIS

9M 2025

Table of Contents

01 [CEO Message & 9M 2025 Key Highlights](#)

02 [Overview](#)

03 [Operational Highlights](#)

04 [Group Income Statement Analysis](#)

05 [Detailed Segment Performance](#)

06 [Cash Flow Analysis](#)

07 [Balance Sheet Analysis](#)

08 [Guidance](#)

09 [Capacity Enhancements and Achievements](#)

10 [Appendix](#)

CEO Message



PureHealth’s performance in the first nine months of 2025 underscores the exceptional strength, resilience, and scalability of our integrated healthcare ecosystem. We delivered another period of strong growth, driven by outstanding execution across both our Care and Cover segments. This success reflects rising patient engagement, higher diagnostic activity, solid insurance renewals, and continued momentum in new customer acquisitions.

Our expansion efforts, from new specialty clinics and advanced diagnostics to targeted international investments, continue to enhance our capacity, capability, and global reach. The completion of the Hellenic Healthcare Group acquisition marks a significant milestone in our journey to build a globally connected, innovation-driven healthcare platform anchored in Abu Dhabi.

Operational excellence remains at the core of everything we do. We have achieved meaningful improvements in efficiency, profitability, and cash generation, while maintaining a strong and flexible balance sheet that enables continued reinvestment in innovation and growth.

As we move toward year-end, our focus remains steadfast: to expand healthcare access, accelerate digital transformation, and deliver world-class care and sustainable value to our patients, partners, and stakeholders, both in the UAE and internationally.

Key Highlights of 9M 2025

Revenue	▲	AED 20.1 Bn +6% YoY	Patient Interactions*	▲	7.7 Mn +11% YoY
EBITDA	▲	AED 3.5 Bn +11% YoY	Operational Beds*	▲	5.5 K +4% YoY
EBITDA Margin	▲	17.3% +0.77 pts YoY	Inpatient Volume*	▲	165 K +9% YoY
Net Profit	▲	AED 1,550 Mn +8% YoY	Outpatient Volume*	▲	6.8 Mn +12% YoY
EPS (LTM)	▲	AED 0.16 +63% YoY	UAE Test Volumes	▲	25.8 Mn +20% YoY
Total Assets	▲	AED 49.5 Bn +2% vs FY24	GWP	▲	AED 5.9 Bn +7% YoY

* Figures Include UAE and UK operations



Overview

Abu Dhabi, November 2025 – PureHealth, the UAE’s largest healthcare group with expanding global operations, reported strong financial results for 9M 2025. Strategic investments in capacity expansion, service diversification, and physician recruitment have significantly increased patient volumes across its UAE and UK facilities. This expanded patient base continues to fuel momentum and growth across PureHealth’s integrated healthcare platform.

PureHealth operates through two strategic verticals - **Care** (Healthcare) and **Cover** (Insurance) - each designed to deliver world-class healthcare services and insurance solutions.

The Care Vertical, which includes the Hospitals, Diagnostics, Procurement, and Technology segments, encompasses a comprehensive ecosystem of medical service providers, including the UAE’s largest healthcare group with 24 hospitals and approximately 5,000 licensed beds, and Circle Health, the UK’s largest private healthcare group, which operates over 50 hospitals with 2,000+ licensed beds. As of October 2025, PureHealth completed the acquisition of its 60% stake in Hellenic Healthcare Group (HHG), Greece and Cyprus’s leading private healthcare provider, strengthening its global platform. HHG financials will be **consolidated in Q4 2025**.

The Cover Vertical represented by Daman, the UAE’s leading health insurer, which provides coverage to over 3.3 million members and processes more than 52 million claims annually. Daman is also expanding into Property & Casualty insurance, reinforcing its position as a diversified insurance powerhouse with a global footprint.

During the first nine months of 2025, PureHealth delivered robust financial results supported by broad-based growth across our segments:

- **Revenue** increased 6.0% YoY to AED 20.1 billion, driven by strong topline growth across both the Cover and Care segments. The Cover segment delivered solid performance, while the Care segment benefited from a significant increase in test volumes, reflecting higher patient activity across the network.
- **EBITDA** grew 11.0% YoY to AED 3.5 billion, while the EBITDA Margin expanded by 0.8 ppts to 17.3%, reflecting continued momentum and operational excellence across both the Care and Cover segments, underpinned by higher volumes and disciplined cost management.
- **Net Income** rose 7.9% YoY to AED 1.55 billion, with the net income margin improving slightly by 0.1 ppts to 7.7%. This growth was achieved despite non-operational items¹ and a higher tax rate of 15%, compared to 9% last year, following the implementation of Pillar Two tax requirements, highlighting exceptional performance within the Cover segment and enhanced operational efficiencies in the Care segment.

PureHealth’s performance underscores the Group’s disciplined execution and operational resilience amid ongoing expansion efforts. With a strong balance sheet, an expanding international footprint, and sustained investment in growth, the company remains well positioned to achieve its medium-term strategic and financial targets.

¹ Share of profit in Ardent was reclassified from being an associate to an investment at fair value post its listing in July 2024. Also, the current period includes the PPA intangibles and SSMC property rental charge, Yas Clinic Group / ADSCC was divested at the beginning of Q2’24



Q3 2025 Operational Highlights

PureHealth maintained strong strategic momentum during the period, accelerating growth through landmark partnerships, targeted acquisitions, and continued execution. The Group continued to enhance its healthcare ecosystem by expanding inpatient and outpatient capacity through new specialty clinics, advancing diagnostic capabilities, and strengthening surgical care services, all supported by the recruitment of top-tier medical professionals. These initiatives reinforce PureHealth's commitment to delivering exceptional, best-in-class healthcare services across an expanding footprint. Key developments across our Care and Cover verticals include:

Care (Healthcare)

Hellenic Healthcare Group



On October 8th, PureHealth completed the acquisition of a 60% stake in Hellenic Healthcare Group (HHG), the leading private healthcare provider in Greece and Cyprus, for EUR 800 million. The transaction implies a 100% equity valuation of EUR 1.3 billion and represents a key milestone in PureHealth's strategy to build a globally connected, innovation-driven healthcare platform anchored in Abu Dhabi. **HHG's financials will be consolidated from Q4 2025.**

The integration of HHG's 11 hospitals and 23 diagnostic centres will expand access to high-quality healthcare for over 1.4 million patients annually. With over 6,900 healthcare professionals, **HHG becomes a core part of PureHealth's international ecosystem**, reinforcing Abu Dhabi's position as a global hub for healthcare excellence and investment.

This acquisition is underpinned by strong demographic tailwinds and private sector growth potential. Greece's rapidly aging population, projected to reach 36% aged 65 and above by 2050, is driving sustained demand for hospital care, chronic disease management, diagnostics, and rehabilitation services. As the **largest private healthcare operator in Greece and Cyprus, with around 35% and 24% market share respectively**, HHG operates the region's only fully integrated platform spanning hospitals, maternity and IVF services, diagnostics, home care, procurement, and digital health.

Building on PureHealth's investment in Circle Health Group in the UK, **the transaction strengthens its European footprint and unlocks synergies in procurement, technology, and clinical expertise**, advancing PureHealth's position as a leading international healthcare platform.

SEHA & SEHA Clinics



SEHA further strengthened its position as the UAE's leading healthcare network through the expansion of specialty clinics, the introduction of new service lines, and a continued focus on elevating both the quantity and quality of patient care delivery.

SEHA also deployed HistoSonics Histotripsy at Tawam Hospital, a groundbreaking, noninvasive therapeutic technology that uses focused sound waves to mechanically destroy diseased tissue without heat, radiation, or surgery, for the treatment of liver tumors. With this milestone, the UAE becomes the third market globally, after the United States and Hong Kong, to introduce this innovative technology.

The SEHA ecosystem continues to be a key growth driver for PureHealth, enabling greater integration and collaboration across our premier specialties. The launch of Corniche Hospital's satellite clinics at Al Rahba Hospital and our SEHA Clinics facilities have enhanced network connectivity, strengthened referral pathways, and advanced SEHA's mission to deliver comprehensive, world-class care across the continuum of services.



SEHA partnered with Schoen Clinic Group, Germany's leading rehabilitation & mental healthcare provider, to deliver world-class Inpatient & Outpatient rehabilitation services, enhancing SEHA's capabilities and establishing Sheikh Tahnoon Bin Mohammed Medical City (STMC) as a regional Centre of Excellence for rehabilitative care.

SEHA Clinics earned multiple Gold and Platinum Awards across key categories at the Arab Hospitals Federation Awards – 2025, including:

- Safety & Quality of Care
- Patient-Centered Care
- Leadership & Governance

The SEHA team successfully completed highly complex, high-risk Stage IV thymoma debulking surgery, requiring advanced thoracotomy techniques and multi-specialty coordination, underscoring our position as a regional leader in complex thoracic and oncologic care.

SSMC

ssmc

SSMC launched the Epilepsy Monitoring Unit (EMU) Clinic in August 2025, reinforcing the company's commitment to advancing neurological care. The clinic provides specialized services for patients with seizure disorders, offering comprehensive diagnostic and treatment capabilities that enhance patient outcomes and strengthen our neuroscience program.

The SSMC team carried out the first ABI Implant within the Abu Dhabi Region marking a major milestone in regional healthcare, offering advanced neuro-ontological care locally and reducing the need for patients to travel abroad.

The team also completed **Abu Dhabi's first Hypoglossal Nerve Implant**, a surgical therapy that stimulates tongue movement to keep airways open. This milestone positions SSMC as a subspecialty centre for treating moderate-to-severe OSA patients intolerant to CPAP therapy.

Rafed



Rafed continues to demonstrate operational excellence, solidifying its position as a strategic partner in healthcare logistics across the broader national healthcare ecosystem.

Rafed has partnered with Abu Dhabi Government to create a Regional Vaccine Distribution Hub. Rafed will act as the logistics partner for the Department of Health's regional vaccine distribution hub, delivering world-class pharmaceutical distribution across the Middle East, Africa, and South Asia.

Looking ahead, the upcoming quarter will see the **expansion of Rafed's service portfolio** with the introduction of **Freight Forwarding and Customs Clearance solutions**, further strengthening its role as an integrated logistics provider.



Cover (Insurance)

Daman



Daman has continued to build upon its momentum from H1 2025 and has significantly improved its performance within this quarter on a YoY basis.

In Q3 2025, Daman deployed an **AI-powered Document Intelligence Platform**, transforming the way it manages and processes over 60 million documents annually into a strategic digital capability, enabling end-to-end intelligent automation across core operations.

Developed by in-house AI experts, this advanced solution leverages artificial intelligence for intelligent classification, validation, and data extraction. The platform delivers exceptional efficiency gains, faster turnaround times for members and providers, and a stronger foundation for Daman's fully digitized operations.

By embedding AI-driven intelligence at the heart of its operations, Daman is not only enhancing productivity and service quality but also **setting new benchmarks for digital excellence and innovation in the regional insurance sector.**

Additionally, Daman, won major awards at 2025 NAFIS awards, in the following categories, honoring exceptional efforts in supporting the UAE's Emiratization initiatives

- First place in the Large-Sized Entities Insurance Sector
- Diamond Category for Emiratisation and Empowering National Talent




Group Income Statement Analysis

AED Mn	Q3 2025	Q3 2024 (Reclassified) ²	Δ%	9M 2025	9M 2024 (Reclassified) ²	Δ%
Revenue	6,527	6,452	+1%	20,101	18,956	+6%
Cost of sales	(4,714)	(4,539)	+4%	(14,979)	(14,019)	+7%
Gross profit	1,813	1,913	-5%	5,122	4,937	+4%
G&A expenses, incl. selling & distribution	(1,355)	(1,255)	+8%	(3,492)	(3,115)	+12%
Finance costs	(185)	(218)	-15%	(578)	(604)	-5%
Other operating income	296	32	+839%	692	310	+123%
Profit before tax	569	472	21%	1,744	1,528	+14%
Income tax expense	(47)	(40)	+19%	(194)	(92)	+111%
Net Profit for the year	522	432	+21%	1,550	1,436	+8%
EBITDA	1,150	970	+19%	3,470	3,126	+11%
Gross Profit Margin	27.8%	29.6%	-1.8ppts	25.5%	26.0%	-0.5ppts
EBITDA Margin	17.6%	15.0%	+2.6ppts	17.3%	16.5%	+0.8ppts
Net Profit Margin	8.0%	6.7%	+1.3ppts	7.7%	7.6%	+0.1ppts

Segment contribution – 9M 2025

● Hospitals ● Health Insurance ● Procurement ● Diagnostic ● Technology



² Previously, government grants were recorded entirely as income. However, the impact of these grants has now been reclassified and appropriately reflected in the respective income and expense accounts



+6% YoY ▲

Revenue Growth

+11% YoY ▲

EBITDA Growth

+8% YoY ▲

Net Profit Growth

+9% YoY ▲

Inpatient Footfall

+12% YoY ▲

Outpatient Footfall

+7% YoY ▲

Emergency Dept
Footfall

Revenue grew over the first nine months of 2025, on the back of strong performance across both the Care and Cover verticals.

The Care segment benefited from higher patient volumes across both UAE and UK, alongside capacity expansion and service enhancement initiatives implemented across PureHealth Hospitals and Clinics.

Meanwhile, **the Cover segment continued to deliver sustained growth** driven by strong policy renewals and new customer acquisitions, underscoring the Group's continued market momentum.

EBITDA increased by 11% YoY to AED 3.5 billion, with the EBITDA margin improving to 17.3%, reflecting operational efficiency gains and the positive impact of service enhancements across the network.

Net profit rose by 7.9% YoY to AED 1.55 billion, with the net profit margin improving by 0.1 percentage points to 7.7%, demonstrating sustained profitability, operational discipline, and resilience across PureHealth's diversified portfolio.



Detailed Segment Performance

Care

AED Mn	Q3 2025	Q3 2024	Δ%	9M 2025	9M 2024	Δ%
Revenue	4,563	4,704	-3%	14,381	13,903	+3%
Total OPEX	(4,281)	(4,175)	+3%	(13,263)	(12,453)	+7%
EBITDA	881	752	+17%	2,692	2,578	+4%
EBITDA margin	19.3%	16.0%	+3.3ppts	18.7%	18.5%	+0.2ppts
Profit Before Tax	315	270	+17%	1,011	1,029	-2%
Net Profit	301	251	+20%	908	986	-8%
Net Profit margin	6.6%	5.3%	+1.3ppts	6.3%	7.1%	-0.8ppts

+3% YoY ▲

Revenue Growth

18.7% ▲

EBITDA Margin

7.7 Mn ▲

Patient Interactions

25.8 M ▲

Testing Volumes

Group healthcare revenue grew by over 3% in the first nine months of 2025, primarily driven by higher patient and diagnostics volumes, supported by ongoing capacity expansion and service enhancements across the network.

In the UAE, revenue growth was underpinned by increased patient volumes, new clinic openings, extended operating hours, and the onboarding of additional specialist physicians, all contributing to enhanced service accessibility and throughput.

In the UK, Circle recorded strong performance, with robust growth across Inpatient, day case and Outpatient revenues, driven by higher-acuity cases. Both private insured and NHS-funded segments recorded solid growth, led by core specialties including orthopedics, general medicine, cardiology & oncology.

Revenue decline in Q3 is within UAE Care primarily due to regulatory changes, including the **implementation of the UPP (Unified Purchasing Program)**, leading to the recognition of pharmacy revenues relating to government mandated programs on a net margin basis, normalizing for the UPP impact, **Q3 revenues achieved high single-digit YoY growth**

EBITDA and EBITDA margin improved during the period (9M 2025), reflecting continued operational efficiency and the positive impact of service quality improvements, which helped offset regulatory changes in both the UAE and the UK.



Net profit was impacted by non-operational items³ and a higher effective tax rate of 15%, compared to 9% in the prior year, following the implementation of Pillar Two tax requirements.

Excluding these effects, underlying performance remained robust, with the normalized net profit margin increasing by 50 basis points to 7.7%, compared to 7.2% in the same period of 2024.

³ Share of profit in Ardent was reclassified from being an associate to an investment at fair value post its listing in July 2024. Also, the current period includes the PPA intangibles and SSMC property rental charge, Yas Clinic Group / ADSCC was divested at the beginning of Q2'24



Cover

AED Mn	Q3 2025	Q3 2024	Δ%	9M 2025	9M 2024	Δ%
Revenue	1,964	1,748	+12%	5,720	5,053	+13%
Total OPEX	(1,788)	(1,618)	+10%	(5,209)	(4,681)	+11%
EBITDA	269	218	+24%	778	548	+42%
EBITDA margin	13.7%	12.5%	+1.2ppts	13.6%	10.8%	+2.8ppts
Profit Before Tax	254	202	+26%	733	499	+47%
Net Profit	220	181	+22%	642	451	+43%
Net Profit margin	11.2%	10.3%	+0.9ppts	11.2%	8.9%	+2.3ppts

+13% YoY ▲

Revenue Growth

+7% YoY ▲

GWP Growth

13.6% ▲

EBITDA Margin

3.3 M ▲

Active Members

+60% ▲

Investment Income
Growth

Daman delivered strong performance in the first nine months of 2025, reinforcing its leadership in the UAE health insurance sector while advancing its diversification strategy. The organization's disciplined execution in its core business has driven growth across all key performance levers, underscoring its focus on sustainable profitability and operational excellence.

Gross written premium (GWP) growth remained strong over the period, supported by high renewal rates and new business acquisition. **Daman's active membership surpassed 3.3 million**, representing a 7% year-on-year increase, reaffirming customer trust and the enduring strength of its value proposition.

Net profit increased 43% year-on-year, driven by disciplined underwriting, enhanced cost management, and a strong investment strategy.

This performance was driven by a **continued focus on operational excellence, enhanced cost management, and a robust investment strategy**, with investment income performing strongly on the back of growth in assets under management and solid market returns.

The company continues to advance its digital transformation journey, leveraging artificial intelligence and intelligent automation to enhance efficiency, reduce costs, and elevate the customer experience.

Beyond health insurance, Daman is making significant progress in expanding into non-health insurance business lines, further diversifying its portfolio and solidifying its position as a leading insurance provider in the UAE.



Balance Sheet Analysis

AED Mn	9M 2025	FY 2024	Δ%
Total Non-Current Assets	27,787	25,844	+8%
Right of use assets	11,200	11,019	+2%
Intangible Assets	8,839	8,644	+2%
Property & equipment	3,240	3,277	-1%
Other non-current assets	4,508	2,904	+55%
Total Current Assets	21,681	22,731	-5%
Trade & other receivables	7,504	4,843	+55%
Cash & Bank Balance	8,284	11,978	-31%
Reinsurance contract assets	1,539	1,527	+1%
Other current Assets	4,354	4,383	-1%
Total Assets	49,468	48,575	+2%
Total Non-Current Liabilities	15,530	16,757	-7%
Lease liabilities	12,793	12,205	+5%
Borrowings	9	1,834	-100%
Employee end of service Benefits	1,530	1,506	+2%
Other non-current liabilities	1,198	1,212	-1%
Total Current Liabilities	13,058	12,081	+8%
Trade & other payables	8,615	7,576	+14%
Contract liability	44	57	-23%
Borrowings	0	26	-100%
Other current liabilities	4,399	4,422	-1%
Total Liabilities	28,588	28,838	-1%
Total Equity	20,880	19,737	+6%
Total Liabilities & Equity	49,468	48,575	+2%



AED Mn	9M 2025	FY 2024	Δ%
Total Bank Debt	1,860	9	-100%
Bank Debt to Equity	0.1 x	0.0 x	-0.1 x
Cash & Bank Balance	8,284	11,978	-31%
Net Debt (Incl. lease liabilities adjusted for restricted cash)	5,896	3,595	+64%
Total Lease Liabilities	13,232	12,512	+6%
Net Debt / EBITDA	1.3x	0.9x	+0.4x

Net Debt Position: The Group's balance sheet remains strong, reflecting disciplined capital management and strong operating cash flows. As of 30 September 2025, PureHealth's Net Debt to EBITDA ratio stood at 1.3x (post IFRS), reflecting a healthy leverage position and prudent financial stewardship.

After accounting for lease liabilities and restricted cash, the Group's net debt position continues to demonstrate solid financial health and **ample balance sheet capacity to support strategic M&A and organic growth initiatives**, in line with the Group's balanced capital allocation strategy.

During the nine months period, PureHealth made an early repayment of AED 1.85 billion in outstanding debt originally due in 2027, underscoring the Group's focus on optimizing capital structure, reducing financing costs, and preserving financial resilience amid continued expansion.



Cash Flow Analysis

AED Mn	Q3 2025	Q3 2024	Δ%	9M 2025	9M 2024	Δ%
Net Profit for the period before tax	569	472	21%	1,744	1,528	14%
Non-cash Adjustments	529	645	-18%	1,684	1,764	-5%
Working Capital Changes ⁴	304	244	24%	(2,404)	(2,521)	-5%
Employees' end of service benefits paid net	(47)	(27)	71%	(148)	(113)	31%
Other	(324)	513	-163%	818	778	5%
Net cash, operating activities	1,031	1,847	-44%	1,694	1,436	18%
Net cash, investing activities	(222)	(846)	-74%	(1,846)	(4,020)	-54%
Net cash, financing activities	(203)	(228)	-11%	(2,802)	501	-659%
Net change in cash & cash equivalents during the period	606	773	-22%	(2,954)	(2,083)	42%
FX rate changes during the period	(13)	41	-132%	65	35	86%
Cash & cash equivalents at the beginning of the period	5,307	5,125	4%	8,789	7,987	10%
Cash & cash equivalents at the end of the period	5,900	5,939	-1%	5,900	5,939	-1%

Cash Flow from Operations: In the first nine months of 2025, the Group generated AED 1,694 million in **positive cash flow from operations**, compared to AED 1,436 million in the same period of 2024, an increase of 18% year-on-year. This strong performance was primarily driven by higher profitability and increased cash inflows from operating activities, supported by the maturity of fixed deposits and the redeployment of capital into higher-yield investment opportunities.

Working capital management also improved year-on-year, reflecting enhanced receivables collection and more efficient supplier management, further strengthening the Group's liquidity position and cash conversion efficiency.

⁴ Working capital does not include reinsurance contract assets/liabilities, other liabilities and restricted cash.



Guidance

Medium-term Financial and Strategic Targets

	9M 2025 Results	Medium-Term Target (2025-2029)
Revenue growth (vs prior period)	6.0%	Mid- to High teens
International business as % of Revenue ⁵	23.9%	c.50%
EBITDA margin	17.3%	Low 20s
CAPEX as % of Revenue	2.5%	<5%
Net Debt ⁶ / EBITDA	1.3x	3.0x

⁵ Share of international business as % of revenue, after intercompany eliminations.

⁶ Incl. lease liabilities, adjusted for restricted cash items.



Capacity Enhancements and Achievements

SEHA & SEHA Clinics



- Successfully performed 97 kidney transplants in 9M 2025, bringing the total to 768 to date.
- Introduced new Pain Management, Plastic Surgery, and Pulmonary Services clinics at Al Rahba Hospital, enhancing access to specialized care.
- Launched dedicated Menopause and Pain Management clinics at Corniche Hospital, broadening women’s health services.
- Expanded specialty care in the Al Ain region with new Orthopedic Joint reconstruction and Surgical proctology services.
- A new Acute Admission Unit (AAU) opened at SKMC, focused on rapid assessment, stabilization, and efficient patient flow, adding 10 new beds and improving overall patient experience.
- Piloted new Pediatric Cardio-Genetic and Pediatric Neuro-Genetic clinics, advancing pediatric specialty care.

SSMC



- Launched an Epilepsy Monitoring Unit (EMU) Clinic in August 2025 as part of the commitment to advancing neurological care, providing specialized services for patients with seizure disorders and offering comprehensive diagnostic and treatment capabilities.
- Continued recruitment of specialist physicians across multiple disciplines to support sustained growth through Q4 2025 and into 2026.
- Maintained weekend clinics and extended evening hours to further expand patient access to care.
- Operating Room (OR) utilization increased to 87% in Q3 2025, up from 75% in Q3 2024, reflecting improved efficiency and throughput.
- Achieved a 17% year-over-year increase in overall surgical volume in Q3 2025, underscoring continued operational momentum.

Circle Health



- Expanded cardiology services through the addition of new specialist physicians, enhancing clinical capability and patient care delivery.
- Achieved Group-wide AFPP accreditation, with Circle becoming the first private hospital group in the UK to earn this recognition.
- Successfully implemented a new Medtronic spinal robot at Ridgeway Hospital, strengthening robotic surgery capabilities.
- Performed approximately 831 robotic-assisted procedures in Q3 2025, reflecting continued growth in advanced surgical activity.



Complex Procedures and Clinical Achievements

SEHA & SSMC



- 23 Liver and 97 Kidney Transplants carried out in 9M 2025.
- SEHA team performed a complex para-aortic lymphadenectomy and partial nephrectomy on a 35-year-old patient, successfully preserving 80% kidney function while completely removing chromophobe kidney cancer. The patient is now cancer-free and requires only routine follow-up.
- SEHA team's milestone achievement in Thoracic oncology with successful completion of highly complex, high-risk Stage IV thymoma debulking surgery, requiring advanced thoracotomy techniques and multi-specialty coordination, underscoring our position as a regional leader in complex thoracic & oncologic care.
- SSMC completed Abu Dhabi's first Hypoglossal Nerve Implant, a surgical therapy that stimulates tongue movement to keep airways open. This milestone positions SSMC as a subspecialty centre for treating moderate-to-severe OSA patients intolerant to CPAP therapy.
- SSMC team performed the first Auditory Brainstem Implant (ABI) within the Abu Dhabi region. An ABI can provide sound to people with profound hearing loss who aren't candidates for cochlear implants (patient present with absent cochlear nerve). The treatment marks a major milestone in regional healthcare, offering advanced neuro-otological care locally and reducing the need for patients to seek treatment abroad.
- SSMC's Maxillofacial, Head and Neck team successfully treated a locally advanced head and neck cancer case using two cycles of neoadjuvant immunotherapy prior to definitive resective and reconstructive surgery. This approach, now emerging as the standard of care for T4 disease, has demonstrated improved survival outcomes in clinical trials.
- A 12-year-old child presenting with a critically low heart rate (30–40 bpm) and complete heart block following a fall underwent successful elective transvenous permanent pacemaker insertion within SEHA.

Circle Health



- 72 Cytoreductive surgeries for Pseudomyxoma performed to date.
- 122 major cardiac cases:
 - 52 Coronary artery bypass grafts (CABG)
 - 31 Aortic valve replacements/repairs
 - 14 TAVI (Transcatheter Aortic Valve Implantation)
 - 25 Mitral valve replacements or repairs
- Robotic Assisted Procedures:
 - 2,250 robotic assisted procedures performed to date
 - 368 VELYS robotic surgeries performed to date
- 112 complex spinal surgeries performed to date.



Appendix

Corporate Structure

Care

Hospital and Other Related Services UAE:
("Hospitals")

- Abu Dhabi Health Services Company ("SEHA")
- SEHA Clinics (formerly "Ambulatory Healthcare Services")
- Sheikh Shakhboub Medical City ("SSMC")
- The Medical Office ("TMO")
- National Rehabilitation Center ("NRC")
- Tamouh Healthcare
- The Life Corner
- Dawak

International:

- Circle Health Group
- Hellenic Healthcare Group (financials are consolidated starting Q4)
- Ardent Health Partners Inc (classified as a minority equity investment (21%))

Diagnostic Services

- PureLab

Procurement and Supply of Medical
Related Products

- Rafed
- One Health

Technology Services and Others

- Pure CS
- PURA
- Talent One

Cover

Insurance Services

- National Insurance Company ("Daman")



About PureHealth

PureHealth (PureHealth Holding PJSC, listed on the Abu Dhabi Securities Exchange: PHH) is the largest healthcare provider in the United Arab Emirates and a leader in the healthcare sector across the MENA region. The Group operates a diverse portfolio that includes over 100 hospitals, over 11,000 licensed beds, insurance, and 143+ laboratories. With its headquarters in Abu Dhabi, PureHealth employs a global team of over 60,000 healthcare practitioners, administrators, and support staff. In 2024, PureHealth catered to over 3.0 million insured members and processed over 52 million insurance claims. As the region's only vertically integrated healthcare platform, PureHealth is committed to transforming healthcare delivery through continuous innovation, operational excellence, and sustainable practices to enhance the well-being of the communities it serves.

Institutional Investor Contact

PureHealth Investor Relations

ir@purehealth.ae

+971 2 2018200

+971 2 2018201

Corporate Headquarters Address

PureHealth Headquarters

Aldar Headquarters Building,

Al Rahah Street,

Abu Dhabi, UAE

Disclaimer

All information included in this document is for general use only and has not been independently verified, nor does it constitute or form part of any invitation or inducement to engage in any investment activity, nor does it constitute an offer or invitation or recommendation to buy or subscribe for any securities in the United Arab Emirates, or an offer or invitation or recommendation in respect of buying, holding or selling any securities of PureHealth Holding PJSC.

PureHealth Holding PJSC does not warranty, express or implied, is made, and no reliance should be placed by any person or any legal entity for any purpose on the information and opinions contained in this document, or its fairness, accuracy, completeness or correctness.

This document may include statements that are, or may be deemed to be, "forward-looking statements" with respect to the Group's financial position, results of operations and business. Information on the Group's plans, intentions, expectations, assumptions, goals and beliefs are for general update only and do not constitute or form part of any invitation or inducement to engage in any investment activity, nor does it constitute an offer or invitation or recommendation to buy or subscribe for any securities in any jurisdiction, or an offer or invitation or recommendation in respect of buying, holding or selling any securities of PureHealth Holding PJSC.

